Clinical trials: Chronic Hepatitis B Infections
Hepatitis B
Hepatitis B Reactivation During Treatment With Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection
Background: Treatment of some diseases can suppress the immune system. This can cause other conditions to reactivate. Recent cases have shown that hepatitis B virus (HBV) reactivates in people who had already recovered from it…
- Trial name
- NCT03248622
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis B Virus Infection
Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection
Current clinical practices has shown promising prospects of the therapy strategy of interferon combined with nucleos(t)ides in patients with chronic hepatitis B, but the safety and efficacy has not been fully studied.
- Trial name
- NCT06544551
- Testing
- Peginterferon Alfacon-2
- Where
- 34 sites in China
- Volunteers
- 336 people
- Sponsor
- Beijing Kawin Technology Share-Holding Co., Ltd.
Chronic Kidney Disease
Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients
The purpose of the study is to demonstrate the safety and immunogenicity of a new investigational hepatitis B virus vaccine, HEPLISAV-B, in patients 18 to 75 years of age who have progressive loss of kidney function.
- Trial name
- NCT00985426
- Testing
- HEPLISAV-B, Engerix-B
- Where
- United States
- Volunteers
- 521 people
- Sponsor
- Dynavax Technologies Corporation
Hepatitis B, Chronic
A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects
This is a Phase 2a, multi-center, randomized, double-blind, placebo-controlled study evaluating the safety, efficacy, and pharmacokinetics (PK) of AL-3778 in combination with Peg-IFN in subjects with Hepatitis B e antigen (HBeAg)…
- Trial name
- NCT03125213
- Testing
- AL-3778, Peginterferon Alfa-2A
- Sponsor
- Alios Biopharma Inc.
Chronic Hepatitis B
Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis
The purpose of this study is to determine if DNA vaccination of chronic HBV patients under treatment with NRTI can restore T-cell responsiveness and delay virologic reactivation after treatment discontinuation.
- Trial name
- VAC-ADN (NCT00536627)
- Testing
- DNA vaccine pCMVS2.S
- Where
- France
- Volunteers
- 70 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Chronic Hepatitis b
The Effect of Metabolic Syndrome on Antiviral Response in People With Chronic Hepatitis B
Chronic hepatitis B (CHB) affects an estimated 292 million people, and causes approximately 800,000 people deaths per year from liver-related complications including cirrhosis and hepatocellular carcinoma, remaining a major…
- Trial name
- NCT05705141
- Volunteers
- 1,000 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Chronic Hepatitis B
Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
The primary objectives of this study are to evaluate the safety and tolerability of study treatment(s) (selgantolimod-containing combination therapies) and to evaluate the efficacy of study treatment(s) as measured by the…
- Trial name
- NCT04891770
- Testing
- Tenofovir Alafenamide, VIR-2218, Nivolumab
- Where
- 26 sites in Australia, Denmark and 6 more
- Volunteers
- 103 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis b
Prediction System of Clinical Endpoint Events for Chronic Hepatitis B Patients
A total of 2000 chronic hepatitis B (CHB) patients with liver biopsy performed at least 1 year after antiviral therapy are enrolled. All the patients will receive original antiviral treatment for the following 10 years.
- Trial name
- NCT03777969
- Where
- 7 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Beijing Friendship Hospital
Chronic Lymphocytic Leukemia
The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib
This observational retrospective study will enroll at least 158 patients affected by Chronic Lymphoid Leukemia (CLL) with previous HBV exposure (HBsAg negative, anti-HBc positive with or without anti-HBs) treated with Ibrutinib…
- Trial name
- LLC1618 (NCT03528941)
- Testing
- Lamivudine, No prophylaxis
- Where
- 23 sites in Italy
- Volunteers
- 109 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Hepatitis B, Chronic
Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection
A First-Time-In-Human study on GSK's therapeutic vaccines to evaluate the reactogenicity, safety, immunogenicity and efficacy on reduction of serum HBV surface antigen in HBV suppressed participants under nucleo(s)tide treatment.
- Trial name
- NCT03866187
- Testing
- ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation, HBc-HBs/AS01B-4 low dose formulation
- Where
- 43 sites in Belgium, France and 7 more
- Volunteers
- 236 people
- Sponsor
- GlaxoSmithKline
Hepatitis B, Chronic
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Participants and Chronic Hepatitis B Patients
This is a multiple-center, randomized, double-blind, placebo-controlled, single-ascending dose and multiple-ascending dose, adaptive parallel study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of…
- Trial name
- NCT02604355
- Testing
- RO7020322
- Where
- 4 sites in Hong Kong, New Zealand and 1 more
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)
The purpose of this study is to determine the efficacy and safety of two dosages of PegIntron for treating hepatitis B e antigen (HBeAg) positive chronic hepatitis B compared with the approved dosage, which is PegIntron 1.0…
- Trial name
- NCT00536263
- Testing
- pegylated interferon alpha-2b
- Volunteers
- 671 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis b
Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB Subjects
The study is a randomized, Double-Blind, Placebo-Controlled study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and food effect of HRS9950.
- Trial name
- NCT04464733
- Testing
- HRS9950
- Where
- China
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Chronic Hepatitis B
Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated
The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of vesatolimod (formerly GS-9620) in adults with chronic hepatitis B (CHB) infection who are currently not being treated.
- Trial name
- NCT02579382
- Testing
- TDF, Vesatolimod
- Where
- 21 sites in United States, Canada and 6 more
- Volunteers
- 192 people
- Sponsor
- Gilead Sciences
Hepatitis B, Chronic
Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B
This study will explore efficacy and safety of Telbivudine in the fifth year of treatment.
- Trial name
- NCT00646503
- Testing
- Telbivudine
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Novartis
Chronic Hepatitis B
Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy
Patients with Chronic Hepatitis B on long term oral antiviral therapy have to continue treatment indefinitely unless they achieve HBeAg seroconversion or HBsAg seroclearance, when therapy can be stopped.
- Trial name
- SWAP (NCT01928511)
- Testing
- peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly, Nucleos(t)ide analogue therapy
- Where
- 4 sites in Singapore
- Volunteers
- 254 people
- Sponsor
- Seng Gee Lim
Hepatitis B, Chronic, Cirrhosis
Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis
This 36-month open-label study of adefovir dipivoxil investigates the clinical benefits of the therapy in chronic hepatitis B patients with advanced fibrosis or cirrhosis confirmed with biopsy.
- Conditions
- Hepatitis B, Chronic, Cirrhosis, Fibrosis, Chronic Hepatitis B
- Trial name
- NCT00347009
- Testing
- adefovir dipivoxil
- Where
- 12 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 155 people
- Sponsor
- GlaxoSmithKline
HBeAg-positive Chronic Hepatitis B
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis…
- Trial name
- NCT01940471
- Testing
- TAF, TDF
- Where
- 160 sites in United States, Australia and 17 more
- Volunteers
- 875 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B Virus
Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation
Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient.
- Trial name
- LiNKeB2 (NCT06853886)
- Testing
- blood sample HBV patient, blood sample healthy volunteers
- Where
- 3 sites in France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
Chronic Hepatitis B
A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.
A clinical study evaluating the pharmacokinetic characteristics and safety of AHB-137 injection in participants with mild to moderate liver dysfunction and those with normal liver function.
- Trial name
- NCT07600788
- Testing
- AHB-137 injection
- Where
- 5 sites in China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Ausper Biopharma Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.